<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04110717</url>
  </required_header>
  <id_info>
    <org_study_id>050719-UCD</org_study_id>
    <nct_id>NCT04110717</nct_id>
  </id_info>
  <brief_title>Electrical Vestibular Stimulation (VeNS) Compared to Sham Control as a Means of Reducing Excess Body Weight</brief_title>
  <official_title>Electrical Vestibular Stimulation (VeNS) Together With a Lifestyle Modification Program, Compared to a Sham Control With a Lifestyle Modification Program, as a Means of Reducing Excess Body Weight and Body Fat.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Neurovalens Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University College Dublin</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Exploristics Ltd</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Compliance Solutions Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Neurovalens Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized, double blind sham controlled clinical trial to evaluate the efficacy of&#xD;
      vestibular nerve stimulation (VeNS), together with a lifestyle modification program, compared&#xD;
      to a sham control with a lifestyle modification programme, as a means of reducing excess body&#xD;
      weight and body fat.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 9, 2020</start_date>
  <completion_date type="Actual">March 23, 2021</completion_date>
  <primary_completion_date type="Actual">March 23, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Double blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Total body weight loss</measure>
    <time_frame>12 weeks</time_frame>
    <description>In kg</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Overweight</condition>
  <condition>Obesity</condition>
  <condition>Overweight and Obesity</condition>
  <condition>Overweight or Obesity</condition>
  <condition>Metabolic Syndrome</condition>
  <arm_group>
    <arm_group_label>Active Device Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>25 subjects randomised to receive active device use plus lifestyle intervention for 3 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Device Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>25 subjects randomised to receive control device use plus lifestyle intervention for 3 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Vestal Device</intervention_name>
    <description>Vestibular nerve stimulator</description>
    <arm_group_label>Active Device Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Control Device</intervention_name>
    <description>Control Device</description>
    <arm_group_label>Control Device Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Hypocaloric Diet</intervention_name>
    <description>Hypocaloric diet</description>
    <arm_group_label>Active Device Group</arm_group_label>
    <arm_group_label>Control Device Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1. Body mass index (BMI) â‰¥ 25 kg/m2 2. Males or Females. Note females of child-bearing&#xD;
             potential must have a negative urine pregnancy test They should agree to follow a&#xD;
             physician-approved contraceptive regimen for the duration of the study period (other&#xD;
             than DMPA injections as this causes weight gain).&#xD;
&#xD;
             3. 18-80 years of age inclusive on starting the study. 4. Ability and willingness to&#xD;
             complete all study visits and procedures; in particular an agreement to engage with:&#xD;
             trying to use the device on a daily basis; the hypocaloric diet weight loss program;&#xD;
             and this provided weight loss support and mentoring.&#xD;
&#xD;
             5. Agreement not to use of prescription, or over-the-counter, weight loss preparations&#xD;
             for the duration of the trial.&#xD;
&#xD;
             6. Agreement not to start smoking tobacco or marijuana for the duration of the study.&#xD;
&#xD;
             7. Access to Wi-Fi (to connect iPod to internet)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1. History of vestibular dysfunction or other inner ear disease as indicated by the&#xD;
             screening questions.&#xD;
&#xD;
             2. History of bariatric surgery, or gastric resection. 3. History of skin breakdown,&#xD;
             eczema or other dermatological condition (e.g. psoriasis) affecting the skin behind&#xD;
             the ears.&#xD;
&#xD;
             4. History of weight loss device implantation (e.g. VBloc Maestro or Abiliti). 5. Use&#xD;
             of a non-invasive weight loss device (e.g. Modius) 6. Hypothyroidism requiring current&#xD;
             treatment with levothyroxine (e.g. Levo-T, Synthroid, Thyroxine) (Other thyroid&#xD;
             disorder patients on stable treatment for at least 3 months are acceptable).&#xD;
&#xD;
             7. Other endocrinological causes of weight gain (e.g. Cushing's disease, Cushing's&#xD;
             syndrome or acromegaly) 8. Previous diagnosis of HIV infection or AIDS (HIV is known&#xD;
             to cause a vestibular neuropathy which would prevent VeNS from working).&#xD;
&#xD;
             9. Diagnosis of cirrhosis, chronic pancreatitis, or liver, kidney or heart failure.&#xD;
&#xD;
             10. Treatment with prescription weight-loss drug therapy in the 6 months before&#xD;
             starting the study.&#xD;
&#xD;
             11. Tobacco or marijuana smoking in the 6 months before starting and for the duration&#xD;
             of the study.&#xD;
&#xD;
             12. Known genetic cause of obesity (e.g., Prader-Willi Syndrome). 13. Body weight&#xD;
             change of more than 20% in either direction within the previous year.&#xD;
&#xD;
             14. Physician-prescribed diet, and/ or current, active member of an organized weight&#xD;
             loss program.&#xD;
&#xD;
             15. Diabetes mellitus (Types 1 &amp; 2). 16. Diagnosis of epilepsy or use of&#xD;
             anti-epileptic medication within six months of starting the study (e.g. for the&#xD;
             treatment of peripheral neuropathy) 17. Chronic (more than a month of daily use)&#xD;
             treatment with opioid analgesic drugs within the last 6 months.&#xD;
&#xD;
             18. Regular use (more than twice a month) of anti-histamine medication within the last&#xD;
             6 months.&#xD;
&#xD;
             19. Use of oral or intravenous corticosteroid medication within 6 months of starting&#xD;
             the study.&#xD;
&#xD;
             20. Use of the beta-blockers atenolol, metoprolol or propranolol within 3 months of&#xD;
             starting the study.&#xD;
&#xD;
             21. Current alterations in treatment regimens of anti-depressant medication for&#xD;
             whatever reason (including tricyclic antidepressants) (Note: stable treatment regimen&#xD;
             for prior 6 months acceptable).&#xD;
&#xD;
             22. An active diagnosis of cancer. 23. A myocardial infarction within the preceding&#xD;
             year. 24. A history of stroke or severe head injury (as defined by a head injury that&#xD;
             required craniotomy or endotracheal intubation). (In case this damaged the&#xD;
             neurological pathways involved in vestibular stimulation).&#xD;
&#xD;
             25. Presence of permanently implanted battery powered medical device or stimulator&#xD;
             (e.g., pacemaker, implanted defibrillator, deep brain stimulator, vagal nerve&#xD;
             stimulator etc.).&#xD;
&#xD;
             26. Psychiatric disorders (including untreated severe depression, schizophrenia,&#xD;
             substance abuse, eating disorder etc.) 27. Current participant in another weight loss&#xD;
             study or other clinical trial. 28. Have a family member who is currently participating&#xD;
             or is planning to participate in this study.&#xD;
&#xD;
             29. Pregnancy 30. History of migraine headaches&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>St. Vincent's University Hospital</name>
      <address>
        <city>Dublin</city>
        <zip>D04 T6F4</zip>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Ireland</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>September 29, 2019</study_first_submitted>
  <study_first_submitted_qc>September 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 1, 2019</study_first_posted>
  <last_update_submitted>March 29, 2021</last_update_submitted>
  <last_update_submitted_qc>March 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Metabolic Syndrome</mesh_term>
    <mesh_term>Overweight</mesh_term>
    <mesh_term>Body Weight</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

